Journey Medical Co. (NASDAQ:DERM) Short Interest Update

Journey Medical Co. (NASDAQ:DERM) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 113,400 shares, an increase of 20.5% from the February 13th total of 94,100 shares. Currently, 1.3% of the company’s shares are short sold. Based on an average trading volume of 69,600 shares, the days-to-cover ratio is currently 1.6 days.

Insider Activity at Journey Medical

In other news, CEO Claude Maraoui sold 18,147 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $5.13, for a total transaction of $93,094.11. Following the transaction, the chief executive officer now owns 2,092,874 shares in the company, valued at approximately $10,736,443.62. This trade represents a 0.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 105,831 shares of company stock worth $536,622. 13.16% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Journey Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nwam LLC bought a new position in Journey Medical during the 3rd quarter valued at about $59,000. Kovitz Investment Group Partners LLC bought a new position in shares of Journey Medical in the third quarter worth about $66,000. Cetera Investment Advisers grew its position in shares of Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock worth $54,000 after buying an additional 2,478 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Journey Medical during the 4th quarter worth approximately $80,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Journey Medical during the 4th quarter worth approximately $174,000. 7.25% of the stock is owned by institutional investors.

Journey Medical Stock Performance

NASDAQ:DERM opened at $5.75 on Thursday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. The firm has a market capitalization of $120.12 million, a PE ratio of -6.12 and a beta of 0.97. The firm’s fifty day simple moving average is $4.78 and its 200 day simple moving average is $5.10. Journey Medical has a 1 year low of $2.85 and a 1 year high of $6.89.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.